CXCL13, a B-cell chemokine, has been proposed as a biomarker in a variety of conditions, some of which can mimic multiple sclerosis and can have very high levels. In this case-control study, cerebrospinal fluid (CSF) CXCL13 was elevated in multiple sclerosis, neuromyelitis optica and other inflammatory neurological controls compared with noninflammatory controls. Levels did not differentiate disease groups. For all subjects taken together, CSF CXCL13 correlated with CSF WBC, oligoclonal band numbers, CSF protein, EDSS, and neurofilament levels. In subgroup analyses, CSF CXCL13 correlated with CSF WBC in neuromyelitis optica and IgG index in multiple sclerosis. Additionally, serum CXCL13 was elevated in neuromyelitis optica.
Introduction
Neuroinflammatory diseases can mimic each other and be difficult to differentiate. Diagnostic tests are often not available or can lack specificity and/or sensitivity. Elevated levels of CXCL13 have been reported in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients 1,2 and even higher levels in neuromyelitis optica (NMO). 3 Additionally, very high CSF levels of CXCL13 have been found in MS mimics, such as central nervous system (CNS) lymphoma and neuroborreliosis, having been proposed as a specific biomarker in the latter disease. 4 We sought to evaluate whether levels of CSF CXCL13 could discriminate neuroinflammatory conditions. Another goal was to determine whether CXCL13 in serum could help differentiate these conditions, as some neuroinflammatory conditions are not confined to the CNS.
CXCL13 is chemotactic for B cells, which are thought to be critical in the pathogenesis of MS and NMO. A role for B cells in MS is suggested by the efficacy of B cell depletion in Phase II studies. 5, 6 CXCL13 is produced in ectopic lymphoid follicles, which are associated with worse outcomes in MS 7 and higher levels may help predict who will develop MS amongst those with clinically isolated demyelinating syndromes. 2 The humoral immune system is implicated in NMO by presence of NMO-IgG and response to rituximab. 8
Methods

Setting and patient selection
CSF and serum samples collected concurrently within months of symptom onset were obtained from our tissue repository. Nine NMO subjects meeting revised criteria 9 and nine MS patients meeting 2005 revised McDonald criteria were matched by gender and age (± 5 years). Diagnosis and Expanded Disability Status Scale (EDSS) score for disability were determined from records by consensus of AHC and EA. Other inflammatory (OIC, n=10) and noninflammatory (NIC, n = 9) neurological disease controls were selected, matching for gender and age (Table 1) . A tenth OIC CSF sample was included to represent viral meningitis, a disease with reported high CXCL13 levels, although serum was unavailable. Two MS, three NMO, and two OIC subjects had received corticosteroids prior to collection. Subsequent analyses showed no significant differences between these subjects and those not on steroids. The local Institutional Review Board approved this study. Informed consent was obtained from each subject at collection.
Sample processing
CSF and serum samples were centrifuged ×1250g and stored at -80°C. Routine CSF analyses were performed by Barnes-Jewish Hospital laboratory. OCB and NMO-IgG were performed at Mayo (Rochester, MN, USA).
ELISA
CXCL13 in serum and CSF was measured by human CXCL13 ELISA (Quantikine; R&D Systems, Minneapolis, MN, USA). CSF myelin basic protein (MBP) and neurofilament (NF) were determined by human MBP ELISA kit and human phosphorylated NF heavy chain ELISA kit, respectively (Beckman Coulter; Brea, CA, USA; and BioVendor; Modrice, Czech Republic).
Statistical analysis
Patient groups were compared with non-parametric Kruskal-Wallis rank test and post-hoc Mann-Whitney U test. Correlation analyses utilized Spearman coefficient (r s ) by rank. PASW Statistics (Armonk, NY, USA) was used.
Results
Patient demographics
Serum and CSF samples from 37 subjects with MS, NMO, OIC, or NIC, matched for age and gender, were studied ( Table 1 ).
CXCL13 levels in CSF and serum
CSF CXCL13 levels were higher in subjects with MS (median 14.5pg/ml (range 8.2-29.5)) than NIC (7.9pg/ml (6.3-18.9)) (p=0.019) (Figure 1(a) ). NMO CSF levels spanned a wide range (24.3pg/ml (8.7-614.6)) and were higher than NIC levels (p=0.008). CSF CXCL13 levels did not statistically differ between NMO and MS (p=0.258). Two NMO samples had very high CSF CXCL13 levels >500 pg/ml (Figure 1(a) ), in the range seen in CNS lymphoma and viral meningitis.
Serum CXCL13 levels were higher in samples from NMO subjects (120.7pg/ml (72.2-516.1)) than in NIC (61.2pg/ml (36.4-211.9)) (p=0.031), with a trend versus MS subjects (94.2pg/ml (37.4-239.6)) (p=0.060) (Figure 1(b) ). Serum CXCL13 was not significantly higher (p=0.471) in MS than in NIC (Figure 1(b) ) samples. CSF and serum levels of CXCL13 were independent of NMO-IgG status.
CXCL13 correlation with other biomarkers
As a surrogate for axonal damage, CSF NF heavy chain levels were measured. NMO subjects (609.2pg/ml (77.6-2918.6)) had higher levels than NIC (44.6pg/ml (24.9-381.1)) (p=0.001) or MS (31.2pg/ml (19.5-466.9)) (p=0.006) ( Supplementary Figure 1(a) online). MS subjects did not differ versus NIC (p=0.666). As a biomarker of demyelination, CSF MBP was measured. MBP was higher in NMO samples (17.79ng/ml (0.74-140.52)) than in NIC (1.14 ng/ml (0.62-2.35)) (p=0.006), and a trend versus MS (1.83 pg/ml (0.30-84.08)) (p=0.063) ( Supplementary Figure 1(b) online). For all subgroups combined, CSF NF correlated with CXCL13 (p=0.013, r s =0.384) ( Supplementary Figure 2 (b) online) and with MBP (p=0.043, r s =0.318) ( Supplementary Figure 2 (c) online). CSF CXCL13 did not correlate with MBP ( Supplementary Figure 2(d) online). For all subgroups combined, CSF CXCL13 levels correlated strongly with CSF WBC (p<0.001, r s =0.667) ( Figure  1(d) ) and moderately with CSF protein (p=0.001, r s =0.487) ( Supplementary Figure 1(c) online) . Within disease groups, CSF WBC correlated strongly with CXCL13 in NMO samples (p=0.038, r s =0.695), but not in MS (p=0.295) (Figure 1(d) ). For subjects with OCB number and IgG index data (nine MS, eight NMO, six NIC, and six OIC), IgG index correlated moderately with CXCL13 (p=0.002, r s =0.512) ( Figure  1(c) ). This correlation was driven by MS subjects (p=0.030, r s =0.717) and not found in NMO (p=0.385). Overall, CSF OCB number correlated with CXCL13 (p<0.001, r s =0.619) ( Supplementary Figure 1(d) online), and with IgG index (p <0.001, r s =0.725).
Biomarker correlation with clinical measures
EDSS was lower in MS (median 3.0 (2.0-8.0)) than NMO (7.5 (3.0-8.5)) (p=0.007). EDSS in both MS and NMO correlated with NF (p<0.001, r s =0.738) (Figure 1(e) ), CSF protein (p=0.003, r s =0.663), CSF white blood cell (WBC) (p=0.005, r s =0.630) ( Supplementary Figure 1(e )-(f) online), and CSF CXCL13 levels (p=0.028, r s =0.449) (Figure 1(f) ).
Discussion
CXCL13 may play a role in MS and NMO pathogenesis by recruiting inflammatory cells into the CNS. Although the sample numbers were low, we found sufficient overlap in CSF CXCL13 levels between groups to believe that CXCL13 will not distinguish the disease groups studied. Some NMO CSF samples contained CXCL13 concentrations in the very high range reported in CNS lymphoma and viral meningitis. Additionally, some MS and NMO samples had low levels in the range of noninflammatory controls. CSF CXCL13 correlated with inflammation (WBC count, total protein, IgG index, and oligoclonal bands (OCB) number) for all samples taken together, but in specific disease subgroups CSF CXCL13 correlated with only some markers. As in prior reports, 1,2 CSF CXCL13 in MS samples correlated with IgG index. We did not find an association with WBC. In samples from NMO subjects, who often have elevated WBC but not IgG index, CSF CXCL13 correlated with CSF WBC but not IgG index. In the present study CSF CXCL13 levels in MS and NMO correlated with disability, which will need to be explored further.
NMO-IgG is often present at higher titers in serum than CSF, 10 suggesting that the autoimmune process in NMO is not CNS restricted. Our finding that NMO patients have elevated serum CXCL13 levels, not described previously, also supports a systemic pathophysiology. Serum and CSF levels of CXCL13 were not correlated ( Supplementary  Figure 1 (a) online), suggesting separate sources or differential degradation in the CNS and periphery.
